Cargando…
Caveolin-1 Dependent Endocytosis Enhances the Chemosensitivity of HER-2 Positive Breast Cancer Cells to Trastuzumab Emtansine (T-DM1)
The humanized monoclonal antibody-drug conjugate trastuzumab emtansine (T-DM1, Kadcyla) has been approved by the U.S. FDA to treat human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer. Despite its effectiveness in most patients, some are initially resistant or develop r...
Autores principales: | Chung, Yuan-Chiang, Kuo, Jang-Fang, Wei, Wan-Chen, Chang, King-Jen, Chao, Wei-Ting |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4501549/ https://www.ncbi.nlm.nih.gov/pubmed/26172389 http://dx.doi.org/10.1371/journal.pone.0133072 |
Ejemplares similares
-
Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
por: Hunter, Francis W., et al.
Publicado: (2019) -
YES1 amplification confers trastuzumab–emtansine (T-DM1) resistance in HER2-positive cancer
por: Wang, Lei, et al.
Publicado: (2020) -
Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases
por: Mills, Matthew N., et al.
Publicado: (2021) -
Radiation dermatitis in patients treated with concurrent trastuzumab emtansine (T-DM1)
por: Corbin, Kimberly S., et al.
Publicado: (2020) -
Activity of trastuzumab emtansine (T-DM1) in 3D cell culture
por: Boyer, Jean Zheng, et al.
Publicado: (2021)